Creative Medical Technology Holdings, Inc. (CELZ) is a pre-revenue biotechnology company with no commercial product revenue in Q1 2026 ($0 vs. $3,000 in Q1 2025). Under a liquidation lens, the balance sheet is dominated by cash and near-cash instruments, which are the only assets with meaningful recovery value. Total assets of $6.44M consist primarily of: cash and equivalents of $5.72M (100% recovery), notes receivable net of $106K (recovery uncertain — these are convertible notes in micro-cap third parties with illiquid conversion mechanics, haircut to 50-70% at best), prepaid and other current assets of $105K (partial recovery, ~50%), intangible assets (patents/licenses) of $378K (zero recovery under liquidation lens), and a $125K investment in an entity controlled by the CEO that has not been formally organized and is carried at cost with no impairment — recovery is speculative, likely zero in a forced liquidation. Total liabilities are minimal at $308K (all current, primarily accounts payable of $293K), yielding GAAP book equity of $6.13M including NCI of $23K. Applying liquidation haircuts: recoverable asset value is approximately $5.72M (cash, 100%) + $53-74K (notes receivable, 50-70% haircut on $106K) + $0 (intangibles) + $0 (CEO-controlled investment) + $53K (prepaids, ~50%) = approximately $5.83-5.85M gross recovery. Net of $308K face-value liabilities, equity recovery is approximately $5.52-5.54M, consistent with the MFFAIS CLV/LLV of ~$5.42M. This is positive, which is atypical and reflects the company's unusual posture: essentially a cash-holding entity burning ~$1.3M per quarter in operating cash with no revenue. Cash declined $1.49M in Q1 2026 from $7.21M at year-end 2025, driven by operating burn of $1.32M and investing outflows of $175K ($125K to the CEO-related SPAC sponsor entity, $50K new note receivable). The company raised no equity in Q1 2026 (vs. $3.4M in Q1 2025 from warrant exercise inducement). At the current burn rate, the implied cash runway is approximately 4-5 quarters before the liquidation recovery turns negative. Two new balance sheet items materialized this quarter: the $125K investment in an unorganized CEO-controlled entity (carried at cost, no impairment, no formal instrument per the filing), and a $50K convertible note receivable from a third-party micro-cap issuer (convertible at 75% of 5-day VWAP, 10% OID-embedded interest). Both are classified in investing and represent capital being deployed into illiquid, related-party-adjacent structures. The filing discusses the Bionance LLC subsidiary, which has consolidated operations and is now generating NCI activity, but the NCI balance is immaterial ($23K). No balance sheet for Bionance's investment portfolio is separately disclosed in XBRL — the Bionance convertible note from 2025 ($60K face, $106K net on balance sheet with premium) is aggregated into NotesReceivableNet. The $378K intangible asset pool (patents and licenses) carries zero recovery value. The accumulated deficit stands at $72.0M, up from $70.6M at December 31, 2025, reflecting the Q1 2026 net loss of $1.41M.
▼ Community Notes